A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

NCT03922204 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Solid Tumor, Adult
B-cell Lymphoma, Adult

Interventions

DRUG: MCLA-145
DRUG: Pembrolizumab (Keytruda)

Sponsor

Merus B.V.